Parkinsons Disease: Epidemiology Forecast to 2026
Parkinsons disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly, affecting 1-2% of individuals ages 65 years and older worldwide. PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression. Age, genetics, sex, and environmental exposure to pesticides increase the risk of developing PD. Conditions such as depression and anxiety have been identified as comorbidities in PD.
For this analysis, GlobalData epidemiologists utilized peer-reviewed studies to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of PD in the 7MM. GlobalData epidemiologists used a consistent methodology across the 7MM to allow for meaningful comparisons of the epidemiological characteristics of PD in each of the 7MM. Additionally, the forecast provided a detailed segmentation of the diagnosed prevalent cases of PD for each country by age, sex, and clinical staging, thereby providing a comprehensive view of PD in the 7MM.
In the 7MM, the diagnosed prevalent cases of PD will increase from 2,284,022 cases in 2016 to 2,858,608 cases in 2026, at an Annual Growth Rate (AGR) of 2.52% per year. When examining the AGR by individual market, GlobalData forecasts that all markets will see an increase in the diagnosed prevalent cases of PD during the forecast period. Since GlobalData epidemiologists held the prevalence constant throughout the forecast period for most population groups, the observed differences in growth are driven primarily by changes in the underlying population dynamics of each market.
- The Parkinsons Disease Epidemiology Forecast Report provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report provides an overview of the risk factors, comorbidities, and global trends for Parkinsons disease (PD) in the 7MM. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by age (18 years and older) and sex. The diagnosed prevalent cases are further segmented by Hoehn and Yahr (HY) clinical staging (Stages I, II, III, IV, and V) at diagnosis.
- The Parkinsons disease epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Parkinsons Disease Epidemiology Forecast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global PD market.
- Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
- Understand magnitude of PD population by clinical stages.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Parkinsons Disease: Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 7
3.3 Global and Historical Trends 8
3.3.1 US 10
3.3.2 5EU 10
3.3.3 Japan 10
3.4 Forecast Methodology 11
3.4.1 Sources 12
3.4.2 Sources Not Used 13
3.4.3 Forecast Assumptions and Methods 13
3.5 Epidemiological Forecast for PD (2016-2026) 16
3.5.1 Diagnosed Prevalent Cases of PD 16
3.5.2 Age-Specific Diagnosed Prevalent Cases of PD 17
3.5.3 Sex-Specific Diagnosed Prevalent Cases of PD 18
3.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging 19
3.6 Discussion 20
3.6.1 Epidemiological Forecast Insight 20
3.6.2 Limitations of the Analysis 21
3.6.3 Strengths of the Analysis 22
4 Appendix 23
4.1 Bibliography 23
4.2 About the Authors 26
4.2.1 Epidemiologist 26
4.2.2 Reviewers 26
4.2.3 Global Director of Therapy Analysis and Epidemiology 27
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 27
4.3 About GlobalData 28
4.4 Contact Us 28
4.5 Disclaimer 28
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for PD 8
Table 2: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages 18 Years, N, 2016 20
1.2 List of Figures
Figure 1 7MM, Diagnosed Prevalent Cases of PD, Both Sexes, Ages 18 Years, 2016 and 2026 5
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages 18 Years, 2016 9
Figure 3: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026 12
Figure 4: 7MM, Sources Used , Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026 13
Figure 5: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, 18 Years, N, 2016 17
Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages 18 Years, N, 2016 18
Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages 18 Years, N, 2016 19
Make an enquiry before buying this Report
Please fill the enquiry form below.